EGFR and non-small cell lung carcinoma: In all NSCLC patients, included initially EGFR mutated or non-mutated patients, Sun et al. reported that pemetrexed is the optimal drug with good efficacy and a tolerable toxicity if it was used as the third-line therapy, the median PFS was 2.83 months with 22% response rate [28].